Cerdelga for a rare genetic disorder gets FDA nod

August 31, 2014 | Sunday | News | By BioSpectrum Bureau

Cerdelga is said to be a hard gelatin capsule containing eliglustat

Cerdelga is said to be a hard gelatin capsule containing eliglustat

Singapore: Gaucher disease occurs in people who do not produce enough of an enzyme called glucocerebrosidase.

The enzyme deficiency causes fatty materials to collect in the spleen, liver and bone marrow.

The major signs of Gaucher disease include liver and spleen enlargement, low red blood cell counts (anemia), low blood platelet counts and bone problems.

Cerdelga is said to be a hard gelatin capsule containing eliglustat that is taken orally.

In patients with Gaucher disease Type-1, the drug slows down the production of the fatty materials by inhibiting the metabolic process that forms them.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

+Country Code-Phone Number(xxx-xxxxxxx)

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

Survey Box

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls